– Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand
– ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
– ASC11 is an oral direct-acting antiviral drug candidate targeting 3-chymotrypsin like protease (3CLpro), combined with ritonavir oral tablets, to treat SARS-CoV-2 infection
HANGZHOU and SHAOXING, China, Jan. 3, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The Company’s COVID-19 pipeline currently includes (i) ritonavir oral tablet (100mg), an authorized product, (ii) ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and (iii) ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor.
The Company owns the only authorized ritonavir oral tablet in China, which passed bioequivalence study. The Company’s ritonavir oral tablet was approved in September, 2021 by China National Medical Products Administration (NMPA). As a pharmacokinetic booster of multiple antiviral protease inhibitors, a low dose ritonavir oral tablet (100mg) is a component of oral direct-acting antiviral drug Paxlovid (Nirmatrelvir+ritonavir). The Company applied the sophisticated formulation technology to significantly increase the human bioavailability of ritonavir which has a very poor solubility and successfully achieved human bioequivalence with the ritonavir oral tablets produced by the Originator, AbbVie. The Company is planning to file generic drug applications for registrations in multiple countries in the world. Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand.
ASC10 is an oral direct-acting antiviral drug candidate targeting RdRp. In vitro data showed significant activity against SARS-CoV-2. ASC10 is an in-house discovered drug candidate with the global intellectual property and commercial rights. Compared to RdRp-targeted Molnupiravir which was approved by US Food and Drug Administration (FDA), ASC10 has a new and differentiated chemical structure. The Company has filed multiple compound and use patent applications. The data from animal studies demonstrated that ASC10 has higher bioavailability when compared to Molnupiravir. The Company plans to submit investigational drug applications (INDs) for clinical trials in China, USA etc. in the first half of 2022.
ASC11 is an oral direct-acting antiviral drug candidate targeting 3CLpro, in combination with the authorized ritonavir oral tablets produced by the Company, to treat SARS-CoV-2 infection. ASC11 is an in-house discovered drug candidate with the global intellectual property and commercial rights. Compared to 3CLpro-targeted Nirmatrelvir which was approved by US FDA, ASC11 has a new and differentiated chemical structure. The Company has filed the compound and use patent applications. The Company plans to submit INDs for clinical trials in China, USA etc. in the second half of 2022. The Company has extensive R&D experience in viral protease inhibitors and successfully developed and commercialized oral HCV protease inhibitor GANOVO® in combination with ritonavir oral tablets for the treatment of chronic hepatitis C.
“At the beginning of COVID-19 in 2020, based on its antiviral platform and R&D experience, the Company made the firm and rapid decision to invest in oral direct-acting antivirals R&D against RdRp and 3CLpro of SARS-CoV-2. Meanwhile, the Company accelerated the development effort to obtain the approval of ritonavir oral tablets in China and successfully achieved the authorization by China NMPA for ritonavir oral tablets,” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, “The Company has tremendous experience in antiviral oral protease inhibitors and successfully developed the fixed-dose combination ASC09F (ASC09+ritonavir) to treat HIV infection, in addition to launching GANOVO®/Ritonavir combination for chronic hepatits C.”
More Stories
Aucun fruit ne devrait être défendu : Dole Sunshine Company exhorte Sa Sainteté à redorer le blason de la pomme
Cette lettre amusante vise à transformer la pomme du péché originel en collation originelle et à attirer l’attention sur l’importance d’une bonne alimentation pour tous SINGAPOUR, 1er juillet 2022 /PRNewswire/ — La calamité du péché originel (et le rôle qu’y a joué la pomme) est indéniablement le désastre de relations publiques le plus catastrophique auquel les fruits […]
UnionPay International seals a deal with NASCU to roll out UnionPay cards
LUSAKA, Zambia, July 1, 2022 /PRNewswire/ — UnionPay International (UPI) today proudly announces a new partnership with National Association of Savings and Credit Unions (NASCU), the apex organisation for all financial cooperatives in Zambia, to issue UnionPay debit Card. This new partnership empowers rural and urban savings groups, village banking, and other forms of cooperative society […]
No Fruit Should be Forbidden: Dole Sunshine Company Urges His Holiness to Redeem the Apple
The lighthearted letter looks to update the apple from Original Sin to Original Snack, and shine the global spotlight on the importance of good nutrition for all SINGAPORE, July 1, 2022 /PRNewswire/ — The calamity of original sin – and the apple’s role in it – is undeniably the most catastrophic PR disaster fruit has […]
Les appareils de forage XCMG soutiennent les infrastructures de transport public et de génie hydraulique au Kenya
NAIROBI, Kenya, 30 juin 2022 /PRNewswire/ — Les appareils de forage XCMG (SHE:000425), y compris les XR400, XR400E et XR360, sont déployés sur de multiples projets de construction pour soutenir le développement des infrastructures locales de transport public et de génie hydraulique. « XCMG s’engage à fournir des technologies de construction avancées et des équipements de construction haut […]
Norway makes fishing vessel data accessible to the world
Norway to become first European nation to share its vessel tracking information on Global Fishing Watch map Lisbon, Portugal, June 30, 2022 (GLOBE NEWSWIRE) — Norway has become the first country in Europe to partner with Global Fishing Watch—an international nonprofit organization dedicated to advancing ocean governance through increased transparency—and will share its vessel tracking […]
Cellebrite Launch of Physical Analyzer Ultra Series Transforms Industry Standard for Digital Data Examination
With recent launches of Physical Analyzer Ultra Series and SaaS-based Cellebrite Premium, Cellebrite delivers powerful, end-to-end Collect & Review offering for digital investigations PETAH TIKVA, Israel and TYSONS CORNER, Va., June 30, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, […]